MeiraGTx Holdings (MGTX) Research & Development (2017 - 2025)
MeiraGTx Holdings (MGTX) reported Research & Development of $30.8 million for Q4 2025, up 28.46% on a YoY basis from $24.0 million in Q4 2024, and down 5.29% quarter-over-quarter from $32.5 million in Q3 2025.
MeiraGTx Holdings (MGTX) Research & Development (2017 - 2025) Analysis & Trends
MeiraGTx Holdings has reported Research & Development for 9 years, with the latest figure at $30.8 million in Q4 2025.
- For the quarter ending Q4 2025, Research & Development rose 28.46% year-over-year to $30.8 million; the trailing twelve-month figure through Dec 2025 stood at $129.6 million (up 8.48% YoY), and the FY2025 full-year result was $129.6 million, up 8.48% from the prior year.
- Research & Development for Q4 2025 stood at $30.8 million, down from $32.5 million in the prior quarter.
- The five-year high for Research & Development was $34.9 million in Q2 2024, with the low at $13.2 million in Q4 2021.
- Historically, Research & Development has averaged $25.3 million across 5 years, with a median of $24.0 million in 2022.
- Annual changes were most pronounced in 2021 — Research & Development surged 367.21% — and 2024, when it decreased 28.76%.
- MeiraGTx Holdings' Research & Development stood at $13.2 million in 2021, then jumped by 65.11% to $21.8 million in 2022, then jumped by 54.7% to $33.7 million in 2023, then declined by 28.76% to $24.0 million in 2024, then climbed by 28.46% to $30.8 million in 2025.
- The last three Research & Development figures came in at $30.8 million (Q4 2025), $32.5 million (Q3 2025), and $33.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 4.32 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 15.66 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 626,092.00 |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -101.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -2.30 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 1.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 357,444.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 961.60 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -58.00 Mn |
| 10 | MeiraGTx Holdings | 910.47 Mn | 844.54 Mn | 74.89 Mn | 30.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 30.81 Mn |
| Sep 30, 2025 | 32.53 Mn |
| Jun 30, 2025 | 33.50 Mn |
| Mar 31, 2025 | 32.78 Mn |
| Dec 31, 2024 | 23.99 Mn |
| Sep 30, 2024 | 26.24 Mn |
| Jun 30, 2024 | 34.93 Mn |
| Mar 31, 2024 | 34.32 Mn |
| Dec 31, 2023 | 33.67 Mn |
| Sep 30, 2023 | 27.86 Mn |
| Jun 30, 2023 | 19.94 Mn |
| Mar 31, 2023 | 22.32 Mn |
| Dec 31, 2022 | 21.77 Mn |
| Sep 30, 2022 | 16.86 Mn |
| Jun 30, 2022 | 24.00 Mn |
| Mar 31, 2022 | 23.10 Mn |
| Dec 31, 2021 | 13.18 Mn |
| Sep 30, 2021 | 21.61 Mn |
| Jun 30, 2021 | 15.19 Mn |
| Mar 31, 2021 | 16.71 Mn |